MGMT is downregulated by promoter methylation in almost half of GBM specimens and its inactivation is associated with enhanced tumor cell sensitivity and the patient response to TMZ.10–12,32,33 This raises the issue that MGMT-negative tumors require other chemoresistance mechanisms for TMZ tolerance. The gene discussed is MGMT; the disease is glioblastoma.